Priority Medicines for Europe and the World Project
"A Public Health Approach to Innovation"
Appendices to Section 8.3
Benefit, Risk and Innovation in Pharmaceutical Research and Development: Opportunities and Issues
8.3.1 Challenge and Opportunity on the Critical Path to New Medical Products [pdf 815KB]
Discussion Paper: The European Medicines Agency
Road Map to 2010: Preparing the Ground for the Future
8.3.3 "Integrating and strengthening the European Research Area" - European Commission [Word 354KB]
Perspectives -- Cutting the Cost of Drug Development?
M.D. Rawlins [pdf
Reprinted by permission from Nature Reviews Drug Discovery Vol. 3 pp. 360-364 Copyright © 2004 Macmillan Magazines Ltd.
8.3.5 NICHM Study [pdf 436KB]
8.3.6 Industry criticism of NICHM Study [pdf 60KB]
8.3.7 NICHM reply to industry criticism [pdf 471KB]
8.3.8 Industry criticism of NICHM reply [pdf 42KB]
EMEA Comments on the project: “Priority